Kobayashi Pharmaceutical Co., Ltd.
Kobayashi Pharmaceutical Co., Ltd. (4967.T) Financial Performance & Income Statement Overview
Access detailed quarterly and annual financial reports for Kobayashi Pharmaceutical Co., Ltd. (4967.T), covering cash flow, earnings, and balance sheets.
Kobayashi Pharmaceutical Co., Ltd. (4967.T) Income Statement & Financial Overview
View the income breakdown for Kobayashi Pharmaceutical Co., Ltd. 4967.T across both annual and quarterly reports.
| Metric | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|
| Revenue | $32.61B | $51.14B | $41.32B | $36.65B |
| Cost of Revenue | $16.28B | $26.23B | $19.38B | $16.84B |
| Gross Profit | $16.33B | $24.91B | $21.94B | $19.45B |
| Gross Profit Ratio | $0.50 | $0.49 | $0.53 | $0.53 |
| R&D Expenses | $0.00 | $9.11B | $0.00 | $2.21B |
| SG&A Expenses | $13.79B | $2.33B | $14.09B | $12.79B |
| Operating Expenses | $13.79B | $17.02B | $14.43B | $15.36B |
| Total Costs & Expenses | $30.07B | $43.26B | $33.82B | $32.21B |
| Interest Income | $51.00M | $48.00M | $39.00M | $51.00M |
| Interest Expense | $4.00M | $5.00M | $6.00M | $13.00M |
| Depreciation & Amortization | $2.19B | $2.006B | -$2.48B | $2.07B |
| EBITDA | $3.93B | $9.88B | $7.10B | $2.75B |
| EBITDA Ratio | $0.12 | $0.19 | $0.17 | $0.08 |
| Operating Income | $2.54B | $7.88B | $7.50B | $4.44B |
| Operating Income Ratio | $0.08 | $0.15 | $0.18 | $0.12 |
| Other Income/Expenses (Net) | -$793.00M | -$1.25B | -$2.48B | -$3.77B |
| Income Before Tax | $1.74B | $6.63B | $5.02B | $669.00M |
| Income Before Tax Ratio | $0.05 | $0.13 | $0.12 | $0.02 |
| Income Tax Expense | $120.00M | $1.91B | $1.11B | $208.00M |
| Net Income | $1.62B | $4.72B | $3.91B | $460.00M |
| Net Income Ratio | $0.05 | $0.09 | $0.09 | $0.01 |
| EPS | $21.85 | $63.53 | $52.57 | $6.19 |
| Diluted EPS | $21.85 | $63.53 | $52.57 | $6.19 |
| Weighted Avg Shares Outstanding | $74.34M | $74.34M | $74.34M | $74.34M |
| Weighted Avg Shares Outstanding (Diluted) | $74.34M | $74.34M | $74.34M | $74.34M |
Financial performance has remained strong, with revenue growing from $36.65B in Q2 2024 to $32.61B in Q1 2025. Gross profit continued to perform well, with margins at 50% in the latest quarter. Operating income reached $2.54B in Q1 2025, holding a steady 8% margin. While R&D and SG&A expenses fluctuated, EBITDA remained robust at $3.93B. Net income dropped to $1.62B, keeping EPS at $21.85. With disciplined cost control and operational efficiency, the company supported consistent profitability, reflecting its ability to deliver stable shareholder value.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan